Platelet rich plasma therapy is a natural therapy based on harnessing the natural healing powers of our own body’s cell components. This has become a highly sought after non surgical procedure for skin rejuvenation and repair based on using your own blood’s platelets and plasma to stimulate new cell growth, and to reverse the signs of ageing like pigmentation, fine lines, skin laxity and scarring.
Regen kits developed by Regen Lab Switzerland, are approved medical devices intended
for the preparation of platelet rich plasma.
The application of platelet rich plasma has been documented in many fields, ranging from hard tissue regeneration to soft tissue management. Due to its ability to induce collagen synthesis by dermal fibroblasts, platelet rich plasma has been proposed as a promising treatment option in the field of skin care.
For a few years, it has been successfully used in numerous skin care applications, including alopecia, scar revision, acne scars, stretch marks, skin rejuvenation and dermal augmentation. For some indications, platelet rich plasma may be used in association with other treatment modalities such as laser, radiofrequency or fat grafting, to improve clinical outcomes.
Platelet rich plasma shortens the different phases of the natural healing process, as it is prepared from autologous blood it eliminates the risk of immune reactions or transmission of infectious diseases. Platelet rich plasma prepared with Regen Kits acts not only as a course of multiple enhanced growth factors, which stimulates cell proliferation, but also as tridimensional (3D) bioactive scaffold, which enhances cell migration and new extracellular matrix deposition.
What anticoagulant does Regen Lab use?
Regen Lab uses Sodium Citrate as their anticoagulant which is a fully reversible anticoagulant. Sodium citrate is anticoagulant and has a neutral pH (pH=7) and has no ancillary effect on the patient. The benefit for using sodium citrate is that the pH level of the plasma does not change like it would with ACD-A anticoagulant. ACD-A is an anticoagulant often used for other plasma preparation, ACD-A is highly acidic (pH=4.5-5), contains hyperomolar dextrose and triggers more discomfort on application than sodium citrate. The anticoagulant comes already in the tube making it a closed loop circuit.
What makes Regen Lab Devices different?
When will patients see results?
Typically, first results are visible 2 weeks after treatment and full results around 4 months after, as platelets stimulate the release of growth factors which assist in collagen regeneration. Increasing the collagen in the patient’s skin means over time the skin will appear younger and fresher looking. Results will vary from one individual to the other.
Things to remember when injecting platelet rich plasma plus ATS combination:
Regen recommends the use of ATS serum to jellify plasma for face injections, the combination of platelet rich plasma with ATS serum should be injected as soon as prepared, as it will rapidly form a clot. Regen Lab advises to use a 1ml syringe filled with 0.9ml of plasma and 0.1ml of ATS serum. The combination is injected using the same technique as a filler though it is not to be described as a filler. It needs to be injected very quickly otherwise it will solidify in the syringe. A platelet gel will form at the site of injection. This will ensure a more localised action, as the product will not diffuse, to treat specific zones such as deep wrinkles or dark circles. For the periorbital area, perform injections of small amounts of the mix around the orbit, avoiding the internal eye’s angle. Immediately after the injections, massage the orbital area from up to down to spread the thrombin gel.
Product Videos and features
|PLATELETS||CONCENTRATION||RED BLOOD CELLS||WHITE BLOOD CELLS||MONONUCLEAR CELLS||LYMPHOCYCTE||MONOCYTE||GRANULOCYTE|
*BCT stands for Blood Cell Therapy
Features and Benefits
Efficiency and Quality
Platelet rich plasma is prepared by taking a small sample of the patient’s blood.
The sample is centrifuged inside Regen Kits using the Regen Lab centrifuge. during centrifugation the blood is separated into plasma,
platelets, white blood cells and red blood cells by the centrifugal force.
The separating gel present in the Regen Kit migrates above the blood cells and isolated the platelets and the plasma.
Platelet rich plasma is then easily collected from the upper part of the tube and can be injected into the treatment site to promote healing, reverse the signs of ageing and matrix remodelling, resulting in skin stimulation. The whole preparation process is simple and takes up to 10 minutes.
It is important to note that this procedure can only be performed by trained practitioners.
The therapeutic effect of platelet rich plasma is due to mediation of the wound healing process, which is initiated by formation of a fibrin clot and the controlled release of the growth factors stored within platelets.
Platelets are responsible for blood clotting but also stimulation of tissue healing, they contain active molecules called growth factors, which allow for an increase in dermal collagen levels as well as in the number and thickness of elastin fibres1. These growth factors promote the healing of damaged skin, including healing of aged skin. Following the plasma injection, the platelets release these growth factors which trigger the surrounding cells to proliferate and thus repair the damage, as a result, the skin volume increases and the skin becomes firmer, more radiant and rejuvenated.
Platelets release multiple growth factors and many other molecules in a controlled manner, in physiological proportions and with a natural balance of proliferative and inhibitory agents. The release of these growth factors stimulates the cells around the injection site, plumping them up, stimulating collagen production and causing a densification of the dermis.1
Autologous Thrombin Serum
Autologous Thrombin Serum is prepared in the same way as platelet rich plasma, from the patient’s own blood. It contains activated Autologous Thrombin.
The addition of Autologous Thrombin Serum (ATS) to the plasma concentrate activates the coagulation process in a physiological manner, including the formation of a 3D fibrin matrix in which the platelets are entrapped.
Thrombin is the enzyme that converts soluble fibrinogen to fibrin monomers which polymerise to form the clot. The clot allows a long lasting growth factor delivery at the treatment site, and its fibrin matrix serves as a scaffold for new tissue reconstruction.
1. Abuaf, O. K., H. Yildiz, H. Baloglu, M. E. Bilgili, H. A. Simsek, and B. Dogan. “Histologic Evidence of New Collagen Formulation Using Platelet Rich Plasma in Skin Rejuvenation: A Prospective Controlled Clinical Study.” [In eng]. Ann Dermatol 28, no. 6 (Dec 2016): 718-24. https://doi.org/10.5021/ad.2016.28.6.718.
2. Redaelli A. Face and neck revitalization with platelet-rich plasma. J Drug Dermatol 2010; 9:466-472
3. Hersant, B., M. SidAhmed-Mezi, F. Picard, O. Hermeziu, A. M. Rodriguez, K. Ezzedine, and J. P. Meningaud. “Efficacy of Autologous Platelet Concentrates as Adjuvant Therapy to Surgical Excision in the Treatment of Keloid Scars Refractory to Conventional Treatments: A Pilot Prospective Study.” [In eng]. Ann Plast Surg 81, no. 2 (Aug 2018): 170-75.
4. Cervelli, V., F. Nicoli, D. Spallone, S. Verardi, R. Sorge, M. Nicoli, and A. Balzani. “Treatment of Traumatic Scars Using Fat Grafts Mixed with Platelet-Rich Plasma, and Resurfacing of Skin with the 1540 Nm Nonablative Laser.” [In eng]. Randomized Controlled Trial. Clin Exp Dermatol 37, no. 1 (Jan 2012): 55-61.
5. Guerid et al. Autologous keratinocyte suspension in platelet concentrate accelerates and enhances wound healing – a prospective randomized clinical trial on skin graft donor sites: platelet concentrate and keratinocytes on donor sites. Fibrogenesis & Tissue Repair 2013; 6:8
6. Gorgu, M., A. Gokkaya, and A. Dogan. “Comparison of Two Anticoagulants for Pain Associated with Platelet-Rich Plasma Injections.” Aesthetic Plast Surg 44, no. 3 (Jun 2020): 955-61. https://doi.org/10.1007/s00266-019-01541-z. https://www.nc-bi.nlm.nih.gov/pubmed/31722064.